Stockscreener 앱 받기
4.79
1.24%
-0.06
시간 외 거래:
4.76
-0.03
-0.63%
전일 마감가:
$4.85
열려 있는:
$4.8
하루 거래량:
587.35K
Relative Volume:
1.04
시가총액:
$279.21M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
17.74
EPS:
0.27
순현금흐름:
$12.42M
1주 성능:
+2.13%
1개월 성능:
+3.46%
6개월 성능:
-1.84%
1년 성능:
+5.97%
1일 변동 폭
$4.66
$4.80
1주일 범위
$4.56
$4.885
52주 변동 폭
$3.295
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Brokers Set Expectations for VNDA Q3 Earnings - MarketBeat
Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN
Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance
Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance
D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace
Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters
Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com
Cycle Pharma maintains takeover offer for Vanda Pharmaceuticals - WHBL
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid By Investing.com - Investing.com UK
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - PR Newswire
Vanda Pharma stock soars as Cycle Pharma reiterates $8/share offer - Seeking Alpha
Cycle Pharmaceuticals offers $8 per share for Vanda By Investing.com - Investing.com UK
Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda - AllSides
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million. - Marketscreener.com
Profit Investment Management LLC Lowers Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Squarepoint Ops LLC Decreases Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
US Supreme Court reportedly declines to hear Vanda patent case - MSN
Dimensional Fund Advisors LP Purchases 292,172 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Sei Investments Co. Sells 123,694 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings By Investing.com - Investing.com Canada
Vanda Pharmaceuticals updates bylaws, clarifies stockholder meetings - Investing.com India
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):